Tests SCI-210 in children and young people with autism
Tests SCI-210 against a placebo in children with autism spectrum disorder.
Plain-language title generated from the registry record
Registry title: SCI-210 in the Treatment of Children and Young Adults With AutismEvaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
Key facts
- Where
- Beersheba, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 18 years old?
Source: NCT05182697, who can take part
Where in Israel
- Clinical Research Center and Negev Autism Center Soroka University Medical Center, Be'er-Sheva, IsraelBeersheba, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neurothera Labs Inc.
- Trial code
- NCT05182697
- Record updated
- 16 May 2025
- Original description
To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)Read full original descriptionShow less
A Randomized, Double-Blind, Sparing-effect Placebo Controlled, With Cross-over Study to Evaluate the Safety, Tolerability and Efficacy of SCI-210 in Children With Autism Spectrum Disorder (ASD)
To evaluate the safety and efficacy of SCI-210 in the treatment of Autism Spectrum Disorders (ASD)
Inclusion: Males or females aged between 5 and 18 years of age (inclusive); Diagnosis of ASD confirmed by the ADOS-2 and DSM-5 criteria; Moderate or greater behavioral problems as measured by a rating of moderate or higher (≥4) on the Clinical Global Impression-Severity (CGI-S); Presence of a parent/legal guardian who is able to consent for their participation and completes assessments regarding the child's development and behavior throughout the study; Patients eligible for cannabis treatment as regulated by the Israeli Ministry of Health, as out lined in the Medical Cannabis unit circular on Licenses for cannabis use, Procedure number 106, version 5 dated Jan 2021.
Exclusion: Children who are already receiving cannabis, antipsychotic drugs, or stimulants; Exposure to any investigational agent in the 30 days prior to trial onset; Subjects who have had changes in non-exclusionary psychotropic medications within 4 weeks of initiation of trial; Children with heart, liver, renal or hematological disorders; History of active seizure disorder or epilepsy; patients who are seizure free for more than 3 years can take part in the study; A current psychiatric diagnosis of bipolar disorder, major depressive disorder (MDD), psychosis, schizophrenia, or post-traumatic stress disorder (PTSD); Allergic to cannabinoids or PEA tablet components; Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he or she were to participate in the study; History of substance abuse (including alcohol abuse or dependence) or laboratory evidence of drug abuse on the Visit 1 drug-screening panel.